2006
DOI: 10.1592/phco.26.12.1694
|View full text |Cite
|
Sign up to set email alerts
|

Pharmacoeconomic Evaluation of Antimuscarinic Agents for the Treatment of Overactive Bladder

Abstract: Among various antimuscarinic agents, solifenacin 5 mg had the lowest costs and highest effectiveness in the treatment of OAB.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
33
0
2

Year Published

2010
2010
2024
2024

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 58 publications
(36 citation statements)
references
References 50 publications
1
33
0
2
Order By: Relevance
“…However, an informatics tool might be useful to prescribers when assessing drug-related risks. A recent paper by Ko et al [21] shows that only 42% of 950 prescribers were able to recognize at least one clinically relevant DDI. Moreover, as shown in a recent Italian population-based survey [9], potential DDIs were mainly related to the co-administration of digoxin and ACE inhibitors, two of the most commonly used drugs.…”
Section: Discussionmentioning
confidence: 99%
“…However, an informatics tool might be useful to prescribers when assessing drug-related risks. A recent paper by Ko et al [21] shows that only 42% of 950 prescribers were able to recognize at least one clinically relevant DDI. Moreover, as shown in a recent Italian population-based survey [9], potential DDIs were mainly related to the co-administration of digoxin and ACE inhibitors, two of the most commonly used drugs.…”
Section: Discussionmentioning
confidence: 99%
“…A pharmaco-economic evaluation in 2006 also determined that solifenacin had the greatest cost-effectiveness when compared to all other anticholinergics, including extendedrelease and transdermal formulations. The study examined clinical outcomes as well as direct drug costs and medical costs associated with overactive bladder-induced comorbidities [19]. This could be an advantage in terms of overall economic burden and may be a consideration in formulary management.…”
Section: Trospium: Key Pointsmentioning
confidence: 99%
“…Úgy tűnik, az EQ-5D index, általános jellegénél fogva, nem vagy alig képes kimutatni az OAB-betegség-gel összefüggő egészségváltozást. Költséghasznossági elemzésekben OAB-ban legtöbbször nem közvetlen EQ-5D-mérésen alapuló hasznosságértékkel számoltak, hanem egy specifi kus (a vizeletürítések gyakorisága, valamint az inkontinens epizódok számából képzett) mé-rőszám és az EQ-5D index közötti korreláció alapján végeztek becslést a különböző OAB súlyossági állapo-tok hasznosságértékeire [19]. A KHQ kérdőívből kalkulált hasznosságértéket is több esetben alkalmazták [14,15].…”
Section: áBraunclassified